<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455831</url>
  </required_header>
  <id_info>
    <org_study_id>221097</org_study_id>
    <nct_id>NCT01455831</nct_id>
  </id_info>
  <brief_title>Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer</brief_title>
  <acronym>PERIOP-01</acronym>
  <official_title>A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The human body has a natural stress response to surgery, including the formation of blood
      clots. This response to surgery has been shown to increase metastases (the spread of cancer
      cells to other organs in the body). These metastases cannot be seen at the time of surgery
      but when they grow into new tumors, the cancer has recurred (come back). A blood thinner
      called &quot;low molecular weight heparin&quot; (LMWH) can suppress the development of metastases after
      surgery in animal experiments. The investigators want to see if giving patients with
      colorectal cancer the blood thinner, LMWH, around the time of surgery can decrease the chance
      of their cancer spreading to other organs (metastases) and coming back (recurrence).

      The investigators need 1075 patients to answer our scientific question. Patients who give
      informed consent will be randomly put into one of two groups, the experimental group and the
      control group. The patients in the control group will be treated with LMWH starting a few
      hours after surgery and every day until they leave the hospital. This is how most patients
      are treated after colon cancer surgery (standard care). The patients in the experimental
      group will be treated with LMWH for a longer period of time, starting on the day they agree
      to have surgery and continuing for two months after surgery. All the patients will be
      followed for at least three years after surgery to find out if their cancer has recurred
      (come back). If LMWH treatment around the time of surgery reduces the chance of recurrence in
      patients with colorectal cancer, it would improve the health and quality of life for these
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>measured at 3 years</time_frame>
    <description>Disease free survival is measured from the time of randomization until local disease recurrence, distant disease recurrence, a new primary colon cancer malignancy, other second primary cancer or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>measured at 5 years</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Thromboembolism events</measure>
    <time_frame>From randomization until 56 days post-surgery</time_frame>
    <description>• VTE events defined as:
a. Deep vein thrombosis: i. non-compressibility of any vein segment from the common femoral vein to the trifurcation of the popliteal vein on compressive ultrasonography ii.persistent intra-luminal filling defect of the iliac, common femoral, superficial femoral, popliteal, posterior tibial or peroneal veins on contrast venography b. Pulmonary embolism: i.high probability V/Q scan ii.positive pulmonary angiogram iii.spiral CT demonstrating intraluminal filling defect in a vessel larger than a segmental artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major surgical site bleeding events</measure>
    <time_frame>From randomization until 56 days post-surgery</time_frame>
    <description>• Major surgical site bleeding events defined as bleeding at the surgical site associated with:
requirement for ≥4 units of packed red blood cells
a drop in Hb of &gt;40 g/L during the first post-op week
bleeding requiring re-operation
fatal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding events (not including the surgical site)</measure>
    <time_frame>From randomization until 56 days post-surgery</time_frame>
    <description>• Major bleeding events (not including the surgical site) defined as:
fatal bleeding, and/or
symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or,
bleeding causing a fall in hemoglobin level of ≥20 g/L, or leading to transfusion of ≥2 units of whole blood or red cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Clinically relevant bleeding events prior to surgery and during the • Clinically relevant bleeding events</measure>
    <time_frame>From randomization to 56 days post-surgery</time_frame>
    <description>Clinically relevant bleeding events prior to surgery and during the follow-up period will be defined as overt bleeding episodes not meeting the inclusion for major bleeding but associated with one of the following:
medical intervention;
an unscheduled contact with a physician;
temporary cessation of anticoagulant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion requirements</measure>
    <time_frame>From randomization to 56 days post-surgery</time_frame>
    <description>Transfusion requirements using the number of units transfused:
Red blood cells
Platelets (Adult dose)
Frozen Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative endpoints</measure>
    <time_frame>5 years</time_frame>
    <description>The correlative endpoints seek to evaluate the pro-metastatic mechanisms of surgery and the antimetastatic mechanisms of LMWH in subjects undergoing surgical resection for colon cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other post-operative (day 0 - day 28) complications</measure>
    <time_frame>Measured from Day 0 until day 28 post-operatively</time_frame>
    <description>Other post-operative (day 0 - day 28) complications as defined using the modified Clavien Classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1075</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <arm_group>
    <arm_group_label>Extended peri-operative thromboprophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard thromboprophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin</intervention_name>
    <description>The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.</description>
    <arm_group_label>Extended peri-operative thromboprophylaxis</arm_group_label>
    <other_name>Innohep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin</intervention_name>
    <description>The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.</description>
    <arm_group_label>Standard thromboprophylaxis</arm_group_label>
    <other_name>Innohep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of pathologically-confirmed invasive adenocarcinoma of the colon or rectum

          2. Pre-operative work-up that reveals potential resectability (CT scan or MRI of the
             abdomen and pelvis) with resection planned within 6 weeks of date of randomization

          3. Pre-operative work-up that reveals no evidence of metastatic disease (CT scan or MRI
             of the abdomen and pelvis and chest X-ray (CXR) or CT scan of the chest)

          4. Age ≥18 years

          5. Hemoglobin ≥ 80g/L

          6. Able and willing to comply with study procedures and follow-up examinations contained
             within the written consent form.

        Exclusion Criteria:

          1. Carcinoma only present in a completely excised polyp (i.e. no residual tumour evident
             in the colon)

          2. Prior VTE including deep vein thrombosis (DVT) or pulmonary embolism (PE)

          3. Requirement for full dose peri-operative anticoagulation

          4. Contraindication to heparin therapy

               1. history of heparin induced thrombocytopenia (HIT)

               2. platelet count of less than 100 x 109/L

               3. actively bleeding

               4. severe hypertension (SBP &gt;200 and/or DBP &gt;120) on more than one reading

               5. documented peptic ulcer within 6 weeks

               6. severe hepatic failure (INR &gt;1.8)

               7. creatinine clearance of &lt; 30 ml/min as calculated by the Cockcroft-Gault formula

               8. Other contraindication to anticoagulation

          5. Participating in another interventional trial that may result in co-intervention or
             contamination (to be determined by sponsor)

          6. History of other malignancies (except for adequately treated basal or squamous cell
             carcinoma or carcinoma in situ) within 5 years of the colorectal cancer diagnosis

          7. Pregnant or lactating

          8. Unable/unwilling to providing informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Carrier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Ann Auer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lesley Yeung, BSc</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>72998</phone_ext>
    <email>lyeung@ohri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penny Phillips, MA</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>73440</phone_ext>
    <email>pphillips@ohri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wim Ceelen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 8E7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanja Grubec</last_name>
      <email>grubac@HHSC.ca</email>
    </contact>
    <investigator>
      <last_name>Marko Simunovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan McKay</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>7432</phone_ext>
      <email>meghan.mckay@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Sunil Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 2R5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Dunn, RN</last_name>
      <email>Karen.Dunn@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Anne O'Connel</last_name>
      <email>Anne.OConnell@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Muriel Brackstone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Pecarskie</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>71065</phone_ext>
      <email>apecarskie@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Rebecca Auer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montfort Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregoire Le Gal, MD</last_name>
      <email>gregoirelegal@montfort.on.ca</email>
    </contact>
    <investigator>
      <last_name>Gregoire Le Gal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queensway Carleton Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Pecarskie</last_name>
      <email>apecarskie@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Joel Weaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sault Area Hospital</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Kovacevich</last_name>
      <phone>705-759-3434</phone>
      <phone_ext>4402</phone_ext>
      <email>KovacevichN@sah.on.ca</email>
    </contact>
    <investigator>
      <last_name>Silvana Spadafora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Haslam, RN</last_name>
      <email>nihaslam@hsnri.ca</email>
    </contact>
    <investigator>
      <last_name>Antonio Caycedo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iriss Mariano</last_name>
      <phone>416-242-1000</phone>
      <phone_ext>81256</phone_ext>
      <email>imariano@hrh.ca</email>
    </contact>
    <investigator>
      <last_name>Steve MacLellan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Taylor, BSc</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>4990</phone_ext>
      <email>emily.taylor@sinaihealthsystem.ca</email>
    </contact>
    <investigator>
      <last_name>Anand Govindarajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Guira</last_name>
      <email>natalia.guira@nygh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Stotland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanthi Kavikondala, BSc</last_name>
      <email>kkavikondala@stjoestoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Shiva Jayaraman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Roke</last_name>
      <email>rachel.roke@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Paul Karanicolas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Shulikovsky</last_name>
      <email>eshulikovsky@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Vicky Tagalakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentine Guiton</last_name>
      <phone>02 98 22 31 41</phone>
      <email>valentine.benech@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Metges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

